Tirzepatide
Dual agonist at GIPR and GLP-1R, 39 residues with a C20 fatty-diacid arm. No glucagon-receptor arm, which is the design difference from retatrutide.
For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.
Before you begin
- • Lot-matched certificate and laboratory notebook
- • Calibrated pipettes, low-binding tubes and suitable PPE
- • Validated solvent, assay reagents and model-specific SOP
- • Appropriate positive, negative and vehicle controls
Required controls
- Vehicle-only negative control
- Matched receptor-null cell line
- Validated reference agonist
- Untreated viability control
Reported protocol
- Weeks 1-4
- 2.5 mg once weekly
- Weeks 5-8
- 5.0 mg once weekly
- Escalation steps
- Increase by 2.5 mg every 4 weeks, up to 15 mg maximum
- Route
- Subcutaneous
Diluent
Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.
Compound-specific: Bacteriostatic or sterile water only, for the same reason as the other lipidated incretin analogs. Discard any vial that does not go fully clear.
Reconstitution concentrations
Solvent volume sets the stock concentration. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 1 mL | 20 mg/mL | 2 mg | 200 mcg |
| 2 mL | 10 mg/mL | 1 mg | 100 mcg |
| 3 mL | 6.67 mg/mL | 666.67 mcg | 66.67 mcg |